CD34 and stroke disorder: As for safety, the risk of MI and stroke did not differ in patients treated with CD34+ cells with respect to placebo (odd ratio (OR) [95%CI]: 0.77 [0.36, 1.63] and 0.50 [0.08, 3.06], respectively), but, in return, the overall risk of mortality was significantly lower in CD34+ cell than in placebo group (0.24 [0.08, 0.73], p = 0.01) (117).